CASSAVA

Simufilam

Following initial Phase 3 clinical trials, this study extends our investigation into Simufilam‘s long-term efficacy for patients with Alzheimer’s disease. Participants continue to receive Simufilam to monitor ongoing effects on improving cognitive functions and slowing down Alzheimer’s disease progression.

Status: ACTIVE, NOT RECRUITING

Application











    All information provided is confidential and will not be given or sold to any other agency without prior consent.